Title:
ENGINEERED IMMUNE CELLS WITH ENHANCED POTENCY AND USES OF SAME IN IMMUNOTHERAPY
Document Type and Number:
WIPO Patent Application WO/2023/141472
Kind Code:
A3
Abstract:
Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express chimeric antigen receptors as well as genetically edited or otherwise engineered enhance the persistence the cells in immunotherapy. In several embodiments, the cells are edited to knock out a target gene that encodes a protein involved in antigen processing and presentation by major histocompatibility complex class I molecules. In several embodiments, a mixture of immune cell types is used, optionally in allogeneic therapy. The engineering and editing of the cells, such as NK cells and/or T cells exhibit enhanced cytotoxicity and/or persistence, as well as reduced risk of reduced graft versus host, host versus graft, and graft versus graft effects.
Inventors:
TRAGER JAMES (US)
CHAN IVAN (US)
WANG DON-HONG (US)
LI GUANGNAN (US)
LAZETIC ALEXANDRA (US)
GUO CHAO (US)
CHAN IVAN (US)
WANG DON-HONG (US)
LI GUANGNAN (US)
LAZETIC ALEXANDRA (US)
GUO CHAO (US)
Application Number:
PCT/US2023/060850
Publication Date:
September 28, 2023
Filing Date:
January 18, 2023
Export Citation:
Assignee:
NKARTA INC (US)
International Classes:
C07K14/725; C07K14/15; C07K19/00; A61P35/00; C07K16/30; C12N5/0783
Domestic Patent References:
| WO2021202832A1 | 2021-10-07 |
Foreign References:
| US20180155717A1 | 2018-06-07 | |||
| US20200399343A1 | 2020-12-24 | |||
| US20210268028A1 | 2021-09-02 |
Other References:
ASHKENAZI AVRAHAM, FAINGOLD OMRI, SHAI YECHIEL: "HIV-1 fusion protein exerts complex immunosuppressive effects", TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 38, no. 7, 1 July 2013 (2013-07-01), AMSTERDAM, NL , pages 345 - 349, XP093096422, ISSN: 0968-0004, DOI: 10.1016/j.tibs.2013.04.003
Attorney, Agent or Firm:
CHRISTENSEN, Michael, R. (US)
Download PDF: